Latest Content

At HLTH 2025, the entrepreneur announced a collaboration between Cost Plus Drugs and President Trump’s TrumpRx platform aimed at improving transparency, reducing drug costs, and reshaping how Americans access their prescriptions.

The collaboration will focus on enhancing cancer therapies through next-gen immuno-oncology and ADC treatments for solid tumors.

“This is about building a powerful bridge between the science that transforms lives and the systems that deliver that transformation,” said Michael J. Hennessy Jr., MJH Life Sciences chairman and CEO, of the BPD Healthcare acquisition.

Jesse Mendelsohn, executive vice president at Model N, discusses the broader issues impacting drug prices.

Peptilogics Founder and CEO, Jonathan Steckbeck, explained that PLG0206’s membrane-active mechanism enables it to destroy both active and dormant biofilm bacteria overcoming a key limitation of traditional antibiotics.

Many of the biodiversity risks associated with pharmaceutical production occur beyond the direct operational control of pharmaceutical businesses, whic means that addressing them requires a collaborative, systemic approach to sustainability.

Cencora CEO Bob Mauch discusses the lessons learned during his first year at the helm—and tackling a complex future for pharma distribution.

The proposed change would add a warning about an increased risk of autism, despite a lack of scientific evidence connecting the medication to the condition.

The company will hold an Extraordinary General Meeting in November to elect new members.

An analysis of pricing data for 12 high-revenue drugs from Medicare Part B and Part D compares US wholesale acquisition costs with the lowest prices in reference countries under the most-favored nation model.

Amid converging pharma pricing trends, such as those triggered by the Inflation Reduction Act, companies must adopt novel operational practices and strategic approaches in line with new parameters for success across a product’s lifecycle.

Galapagos scales back its cell therapy business to enhance efficiency and focus on transformative opportunities, impacting over 365 employees globally.

Sanofi's Tzield gains FDA's expedited review, promising rapid access to innovative treatment for type 1 diabetes and addressing significant medical needs.